Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Assess which Dividend Aristocrats ETF offers the lowest expenses while maintaining solid diversification and dividend potential for your portfolio.
27,511 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Two market behemoths, two roadmaps: Palantir’s enterprise AI software and SanDisk’s hyperscale memory hardware race t...
June data showed payroll gains stalled while prime-age participation fell, signaling hidden weakness beneath the surf...
Looking for passive income that can edge toward 8% annual returns? This guide covers seven loan-based options, how th...
A CFO selling NuScale stock can spark questions about the company’s outlook. This guide breaks down what the move mig...
A yearly reshuffle of Medicare Part D pharmacy networks can swing out-of-pocket costs for maintenance meds. Investors...
A Chinese open-weights AI model stirred markets and sent Nvidia shares lower. This piece explains why the dip could a...
Bitcoin's Divergence From Nasdaq raises questions about dollar liquidity and credit conditions. This article breaks d...
Stocks wiggle as CoreWeave drops on news of Blue Owl’s failed $4B debt placement. Experts say the financing hiccup co...
Amazon's latest earnings highlighted a bold AI bet and a hefty capex agenda. This article breaks down what it means f...
An emergency U.N. Security Council meeting escalated tensions as Israel and the U.S. push back against calls for rest...
CrowdStrike delivered a record Q4 with key ARR milestones, prompting mixed but bullish reactions from four top banks....